Literature DB >> 20822649

Epidemiology of conventional cardiovascular risk factors among hypertensive subjects with normal and impaired fasting glucose.

A A Akintunde1.   

Abstract

BACKGROUND: Impaired fasting or glucose tolerance and/or diabetes can occur with hypertension, which theoretically predicts a worse cardiovascular risk profile, and consequently requires intensive cardiovascular risk management.
OBJECTIVES: To characterise the frequency of the occurrence of conventional cardiovascular risk factors among hypertensive subjects with impaired fasting blood glucose.
METHODS: We studied 120 hypertensive subjects and 80 age- and sex-matched normotensive controls. Relevant history, clinical examination, laboratory and other tests were undertaken. Body mass index was determined. Informed consent was obtained from all participants, and ethical approval was obtained.
RESULTS: There was no statistically significant difference between the age and gender of the hypertensive subjects and the controls (55.1+/-10.83 v. 54.7+/-10.89 years, p=0.76). The serum fasting lipids were higher, but not statistically significantly, among the hypertensives than the controls (triglycerides 1.23+/-0.50 v. 1.22+/-0.48, p=0.900; total cholesterol 4.51+/-1.52 v. 4.38+/-0.84, p=0.842; LDL 2.51+/-1.41 v. 2.4+/-0.63, p=0.811, respectively). The prevalence of impaired glucose tolerance among newly presenting hypertensive subjects was 30.0%. Hypertriglyceridaemia (38.9% v. 6.0%, p=0.038), hypo-HDL cholesterolaemia (52.7% v. 31.0%, p=0.028) and visceral obesity (52.8% v. 27.4%, p=0.036) were statistically more prevalent among hypertensive subjects with impaired glucose tolerance than among those with normal glucose tolerance.
CONCLUSION: The prevalence of impaired glucose tolerance among newly presenting hypertensive subject is very high, and they have more clusters of cardiovascular risks than those without impaired glucose tolerance. The former therefore need intensive cardiovascular assessment and appropriate preventive and treatment modalities. Glucose parameters of newly presenting hypertensive subjects must be determined to evaluate their cardiovascular risk profile.

Entities:  

Mesh:

Year:  2010        PMID: 20822649     DOI: 10.7196/samj.3180

Source DB:  PubMed          Journal:  S Afr Med J


  7 in total

1.  Relationship between carotid artery stiffness and total serum homocysteine in coronary slow flow phenomenon: a high-resolution echo-tracking study.

Authors:  Song Yang; Wen He; Yi Li; Fu-Min Wang; Lu Yin; Li-Juan Du
Journal:  Quant Imaging Med Surg       Date:  2022-05

2.  The ten-year risk of developing cardiovascular disease among public health workers in North-Central Nigeria using Framingham and atherogenic index of plasma risk scores.

Authors:  Olubunmi Abiola Olubiyi; Bosede Folashade Rotimi; Munirat Ayoola Afolayan; Bilqis Wuraola Alatishe-Muhammad; Olufemi Mubo Olubiyi; Ahmed Dahiru Balami
Journal:  BMC Public Health       Date:  2022-04-27       Impact factor: 4.135

3.  Pre-hypertension and hypertension in college students in Kuwait: a neglected issue.

Authors:  Hana T Al-Majed; Ali A Sadek
Journal:  J Family Community Med       Date:  2012-05

4.  Antihypertensive Medications Adherence Among Nigerian Hypertensive Subjects in a Specialist Clinic Compared to a General Outpatient Clinic.

Authors:  A A Akintunde; T S Akintunde
Journal:  Ann Med Health Sci Res       Date:  2015 May-Jun

5.  Knowledge, attitudes and management skills of medical practitioners regarding weight management.

Authors:  Vangile B Mkhatshwa; Gboyega A Ogunbanjo; Langalibalele H Mabuza
Journal:  Afr J Prim Health Care Fam Med       Date:  2016-11-29

6.  Incidence and Risk Factors for Progression to Diabetes Mellitus: A Retrospective Cohort Study.

Authors:  Min Kyung Hyun; Jong Heon Park; Kyoung Hoon Kim; Soon-Ki Ahn; Seon Mi Ji
Journal:  Int J Environ Res Public Health       Date:  2021-12-23       Impact factor: 3.390

7.  Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria.

Authors:  Charles U Osuji; Emeka G Omejua; Emmanuel I Onwubuya; Gladys I Ahaneku
Journal:  Int J Hypertens       Date:  2012-12-04       Impact factor: 2.420

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.